Avidity Biosciences, Inc. (RNA)

NASDAQ: RNA · IEX Real-Time Price · USD
23.93
-0.49 (-2.01%)
At close: Mar 18, 2024, 4:00 PM
23.94
+0.01 (0.04%)
After-hours: Mar 18, 2024, 7:49 PM EDT
-2.01%
Market Cap 1.97B
Revenue (ttm) 9.56M
Net Income (ttm) -212.22M
Shares Out 79.72M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,889,737
Open 24.50
Previous Close 24.42
Day's Range 23.66 - 25.12
52-Week Range 4.83 - 26.24
Beta 0.71
Analysts Buy
Price Target 35.43 (+48.06%)
Earnings Date May 7, 2024

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial;... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 253
Stock Exchange NASDAQ
Ticker Symbol RNA
Full Company Profile

Financial Performance

In 2023, RNA's revenue was $9.56 million, an increase of 3.64% compared to the previous year's $9.22 million. Losses were -$212.22 million, 22.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for RNA stock is "Buy." The 12-month stock price forecast is $35.43, which is an increase of 48.06% from the latest price.

Price Target
$35.43
(48.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Avidity Biosciences Honors Rare Disease Day®

SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

18 days ago - PRNewsWire

Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellingto...

18 days ago - PRNewsWire

Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights

Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living w...

19 days ago - PRNewsWire

Avidity Biosciences to Participate in Upcoming Investor Conferences

SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

20 days ago - PRNewsWire

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

26 days ago - PRNewsWire

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth

Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024  -- AOC 1001 data for DM1 in Q1, AOC 1020 d...

2 months ago - PRNewsWire

Avidity Stock Soars on Collaboration Deal With Bristol Myers

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Other symbols: BMY
3 months ago - Barrons

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent...

Other symbols: BMY
3 months ago - Market Watch

Avidity Biosciences to Participate in Upcoming Investor Conference

SAN DIEGO , Nov. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

4 months ago - PRNewsWire

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term s...

4 months ago - PRNewsWire

Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society

SAN DIEGO , Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

6 months ago - PRNewsWire

Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity joins with MDF community lead...

6 months ago - PRNewsWire

Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference

SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

7 months ago - PRNewsWire

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights

Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nas...

7 months ago - PRNewsWire

Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day

Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD Company anticipates data from a preliminary assessment in half of the participants i...

9 months ago - PRNewsWire

Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress

SAN DIEGO , June 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co...

10 months ago - PRNewsWire

Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Positive topline data from AOC 1001 Phase 1/2 MARINA™ trial demonstrated functional improvement, disease modification and favorable safety and tolerability profile in people living with myotonic dystr...

11 months ago - PRNewsWire

Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1

SAN DIEGO, April 27, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

11 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA

NEW YORK , April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advis...

11 months ago - PRNewsWire

Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting

SAN DIEGO, April 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

1 year ago - PRNewsWire

Avidity's stock falls after sharing additional data about partial clinical hold

Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic dy...

1 year ago - Market Watch

Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

1 year ago - PRNewsWire

Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights

SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

1 year ago - PRNewsWire

Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader

W. Michael Flanagan, Ph.D. named chief scientific and technical officer SAN DIEGO , Feb. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to deli...

1 year ago - PRNewsWire

Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...

1 year ago - PRNewsWire